Look behind the lecture: how and when should evidence from patient preference studies be integrated into HTA

14 Apr 2022

Written by Irina Cleemput (KCE)

COVID-19 Health technology assessment Interviews ISPOR Outcomes research Stakeholder engagement

Following the session at ISPOR—The Professional Society for Health Economics and Outcomes Research's (NJ, USA) Virtual ISPOR Europe 2021 (November 30–December 3), Irina Cleemput of the Belgian Health Care Knowledge Centre (KCE; Brussels, Belgium) discusses why including patient preference (PP) studies into health technology assessments (HTA) is valuable for establishing impactful outcomes. Please could you introduce yourself, your organization(s) and provide a brief summary of your career to date? I am the scientific program director at the KCE, with a PhD in health economics and I have been working at KCE since 2004. After finishing my PhD at KU Leuven...